The 305,000-square-foot facility, located in Anagni, Italy, is a biologics, sterile and oral solid dose manufacturing and packaging building. It primarily serves as Bristol-Myers’ launch facility for new medicines.
“The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply,” Alessandro Maselli, president and chief operating officer, Catalent, said. “Anagni provides our European customers with great biologics and oral dose capabilities that can help us reduce time-to-market, simplify tech transfers, and minimize program risk.”
As part of the deal, Catalent plans to make further investments into the site’s growth and will continue to manufacture Bristol-Myers’ current product portfolio there.